Rocket Pharmaceuticals develops gene therapies for rare inherited heart diseases. It last closed at $2.11 on Nov 17, down 2.31% on the day. The average 12-month price target from 5 analysts is $8.60 (+307.6% from the last close), with a high of $15.00 and a low of $4.00. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell).
Each firm's latest rating on RCKT in the past 90 days
Average 12-month target
$8.60
▲ 307.6% upside
Based on 5 analysts who set a price target on RCKT in the past 90 days. The average target is $8.60, with a high of $15.00 and a low of $4.00, compared with the last close of $2.11.
Low $4.00Avg $8.60High $15.00
Blue marker: last close $2.11
Highest target$15.00
Average target$8.60
Lowest target$4.00
Latest rating changes
Goldman SachsUpgrade
Oct 8Hold$4
Leerink PartnersMaintained
Oct 7Hold$4
WedbushReiterated
Sep 16Buy$15
NeedhamUpgrade
Sep 16Buy$9
Chardan CapitalMaintained
Sep 1Buy$11
Date
Firm
Action
Rating
Price target
Oct 8
Goldman Sachs
Upgrade
Hold
$4
Oct 7
Leerink Partners
Maintained
Hold
$4
Sep 16
Wedbush
Reiterated
Buy
$15
Sep 16
Needham
Upgrade
Buy
$9
Sep 1
Chardan Capital
Maintained
Buy
$11
Loading…
Technical Analysis
RCKT · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 14% below its 20 day and 25% below its 50 day average. It is 60% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the 52 week low at $2.03, and the nearest resistance the Pivot R1 at $2.19.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.5%/day
Key levels
$5.4552 week high+158.3%
$3.38200 day average+60.2%
$3.11100 day average+47.4%
$2.6550 day average+25.6%
$2.4020 day average+13.7%
$2.38Swing high (Oct 21)+12.8%
$2.19Pivot R1+3.8%
$2.11Pivot+0.0%
$2.11Last close
$2.0352 week low−3.8%
$2.03Pivot S1−3.8%
Indicators
RSI (14)
35.59
Weak, oversold below 30
Neutral
MACD
-0.10
Below its signal line
Bearish
Stochastic
12.2
Near the bottom of its range
Oversold
ADX (14)
16.2
No clear trend
Williams %R
-87.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-169.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−15.9%
Change over 10 sessions
Bearish
ATR (14)
$0.18
Typical daily range, 8.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 21.8%/day
Key levels
$5.4552 week high+158.3%
$3.38200 day average+60.2%
$3.11100 day average+47.4%
$2.6550 day average+25.6%
$2.4020 day average+13.7%
$2.38Swing high (Oct 21)+12.8%
$2.19Pivot R1+3.8%
$2.11Pivot+0.0%
$2.11Last close
$2.0352 week low−3.8%
$2.03Pivot S1−3.8%
Indicators
RSI (14)
35.09
Weak, oversold below 30
Neutral
MACD
-0.35
Below its signal line
Bearish
Stochastic
7.7
Near the bottom of its range
Oversold
ADX (14)
15.1
No clear trend
Williams %R
-95.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-111.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−37.0%
Change over 10 sessions
Bearish
ATR (14)
$0.46
Typical daily range, 21.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RCKT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RCKT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow RCKT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RCKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCKT is in one of them and how their past RCKT trades turned out.
Rocket Pharmaceuticals is a biotechnology company based in New York that develops gene therapies for rare inherited diseases. Its main focus is heart conditions caused by genetic mutations, such as certain forms of cardiomyopathy. The company uses modified viruses that do not cause disease to deliver working copies of genes into patients' cells. Its treatments are aimed at patients with rare conditions, and the company works with healthcare providers, payors and patient communities.